Close

Press Releases

ChargePoint Technology Launches First-of-its-kind Smart Monitoring Technology at ACHEMA 2018

Powder containment and aseptic transfer valve specialist, ChargePoint Technology, has launched a unique Smart monitoring hub to support efficiency and safety within chemical and pharmaceutical manufacturing processes. The company will be exhibiting its new VERIFI solution...

CRF Healthโ€™s eCOA Solution Selected for Large-Scale Insomnia Study by Innovative European Pharmaceutical Company

CRF Health, the leading provider of patient-centered eSource for the life sciences industry, announced that its electronic Clinical Outcome Assessment (eCOA) solutions have been selected for a significant insomnia trial by a European pharmaceutical company specializing in the discovery...

WuXi STA Changzhou Site Passes First U.S. FDA Inspection

STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec, announces that its active pharmaceutical ingredient (API) R&D and manufacturing facility located in Changzhou, China has secured Pre-Approval Inspection (PAI) for two APIs from the U.S. FDA โ€“ with no...

Largest-ever HKTDC Hong Kong International Medical Fair Opens

Organised by HKTDC and co-organised by the Hong Kong Medical and Healthcare Device Industries Association, the ninth edition of the HKTDC Hong Kong International Medical Devices and Supplies Fair opened today and continues through 9 May at the Hong...

Professional LAB Marketplace for Asia โ€“ Thailand LAB INTERNATIONAL 2018

The 8thInternational Trade Exhibition and Conference on Analytical Laboratory Equipment & Technology, Biotechnology & Life Sciences and Chemical & Safety will return again during 12thโ€“ 14thSeptember 2018 at EH102-103, BITEC, Thailand.ย  Last year Thailand LAB INTERNATIONAL...

Lonza to Host New Webinar: โ€œEngineering Culture Platforms to Mimic Liver Diseasesโ€

On 16 May 2018, Lonza is hosting a free 60-minute webinar on innovative technologies for building advanced human liver culture platforms that better mimic common liver diseases, such as non-alcoholic fatty liver disease, liver fibrosis and hepatitis B viral...

Biogen and Neurimmune Announce Option Exercise for Alzheimerโ€™s Disease Investigational Treatment Aducanumab

Biogen and Neurimmune announced that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab, Biogenโ€™s Phase 3 investigational treatment for early Alzheimerโ€™s disease. Biogen will...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป